The novel hydroxynaphthoquinone 566C80 inhibits the development of liver stages of Plasmodium berghei cultured in vitro

The novel hydroxynaphthoquinone 566C80 inhibits the development of liver stages of Plasmodium berghei cultured in vitro

The causal prophylactic activity of the novel hydroxynaphthoquinone, 566C80, was assessed against the exo-erythrocytic (EE) stages of Plasmodium berghei cultured in the human hepatoma cell line, HepG2. 566C80 was found to be highly active as an inhibitor of EE development and was more active than th...

Full description

Saved in:
Bibliographic Details
Published in:Parasitology Vol. 106 ( Pt 1); p. 1
Main Authors: Davies, C S, Pudney, M, Nicholas, J C, Sinden, R E
Format: Journal Article
Language:English
Published: England 01-01-1993
Subjects:
Animals
Antimalarials - pharmacology
Antiprotozoal Agents
Atovaquone
Dose-Response Relationship, Drug
Humans
Liver - parasitology
Morphogenesis - drug effects
Naphthoquinones - pharmacology
Plasmodium berghei - drug effects
Plasmodium berghei - growth & development
Pyrimethamine - pharmacology
Tumor Cells, Cultured
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The causal prophylactic activity of the novel hydroxynaphthoquinone, 566C80, was assessed against the exo-erythrocytic (EE) stages of Plasmodium berghei cultured in the human hepatoma cell line, HepG2. 566C80 was found to be highly active as an inhibitor of EE development and was more active than the established causal prophylactic pyrimethamine. A 566C80 concentration of 1.85 x 10(-9) M, added 3 h after sporozoite invasion, reduced the numbers of EE forms visible at 48 h by 50 degrees o, while the equivalent concentration of pyrimethamine was 1.95 x 10(-8) M.
ISSN:0031-1820
DOI:10.1017/S0031182000074746